pharmaceutical sales

Eli Lilly raised its full-year sales outlook by $2 billion driven by skyrocketing sales of diabetes/weight-loss drugs Zepbound and Mounjaro. This massive revenue increase demonstrates the commercial success of GLP-1 medications, positioning Lilly to capture significant market share in the growing obesity treatment sector.